BioSpace News Archive

Lattice Biologics Ltd. (TSX-V: LBL) (OTCBB: LBLTF) (“Lattice Biologics” or the “Company”) is pleased to announce that it has obtained TSX-V approval to issue 16,760,000 common shares of the Company to settle outstanding debt.

Opthea Limited (ASX:OPT) will host a conference call to discuss the results of the Company’s Phase 2a clinical trial evaluating the safety and efficacy of OPT-302 administered in combination with Eylea® (aflibercept) for treatment of persistent diabetic macular edema (DME).

Effective today, Cellbox Solutions GmbH announces the appointment of former Head of Biosolutions R&D from Lonza Pharma and Biotech, Dr. Herbert A. Mueller-Hartmann, as the new Head of Research and Developmen

Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) today announced that its Seattle-based subsidiary Just - Evotec Biologics, Inc. has entered into an agreement with Advanced BioScience Laboratories, Inc.

RELIEF THERAPEUTICS Holding AG “Relief” and its U.S. partner, NeuroRx, Inc. announced that the Phase 2/3 clinical trial evaluating RLF-100 as a treatment for critical COVID-19 with respiratory failure has been expanded to include patients receiving high flow oxygen and noninvasive ventilation, in addition to those on ventilators.

CSL Behring, a global biotherapeutics leader, announced results of a Phase 2 clinical trial for garadacimab, an investigational novel Factor XIIa-inhibitory monoclonal antibody in development as a preventive treatment in hereditary angioedema.

Data published evaluates fibrodysplasia ossificans progressiva (FOP) natural disease progression

Nanobiotix has been able to maintain business continuity and drive key strategic priorities throughout the first half of 2020.

Mainstay Medical Holdings plc, announced that ReActiv8, its implantable restorative neurostimulation system to treat disabling Chronic Low Back Pain, has been approved for inclusion in the Prostheses List of reimbursed products in Australia, effective as of 1 July 2020.

HeiQ Viroblock NPJ03 is among the first textile technologies in the world to be proven effective against SARS-CoV-2 in the laboratory.